MedPath

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD

Phase 3
Terminated
Conditions
Macular Degeneration
Interventions
Registration Number
NCT00499590
Lead Sponsor
OPKO Health, Inc.
Brief Summary

The purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to Lucentis® given every 4 weeks to people with wet AMD. Patients will be assigned at random (like tossing a coin) to receive one of three treatments options for 104 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
338
Inclusion Criteria
  1. Patients must be age 50 years or older
  2. Patients must have predominantly classic, minimally classic or occult with no classic lesions secondary to Age Related Macular Degeneration.
  3. The study eye must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen equivalent).
  4. Patients must be willing and able to return for scheduled monthly follow-up visits for two-years.
Exclusion Criteria
  1. Prior pharmacologic treatment for AMD in the study (patients can not have previously received Avastin®/Lucentis®, Macugen®, or any other anti-VEGF agents, steroid treatments, PDT, radiation treatment, or any experimental therapies for AMD in the study eye)
  2. Any intraocular surgery of the study eye within 12 weeks of screening
  3. Previous posterior vitrectomy of the study eye
  4. Advanced glaucoma or intraocular pressure above 22 mm Hg in the study eye despite treatment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CbevasiranibBevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 \& 6.
AranibizumabLucentis® (0.5mg) every 4 weeks.
BbevasiranibBevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 \& 6.
Primary Outcome Measures
NameTimeMethod
Visual Acuityweek 60

avoidance of 3 or more lines of vision loss

Secondary Outcome Measures
NameTimeMethod
Need for Rescue Therapy, Time to Rescue Therapy, and Number of Patients With a 3 or More Line Gain in VisionWeek 60

Trial Locations

Locations (60)

Retina Institute of California (site 207)

🇺🇸

Pasadena, California, United States

Miramar Eye Specialists Medical Group (site 245)

🇺🇸

Ventura, California, United States

Florida Eye Microsurgical Institute, Inc. (site 217)

🇺🇸

Boynton Beach, Florida, United States

Eye Medical Center (site 287)

🇺🇸

Fresno, California, United States

Retina Health Center (site 247)

🇺🇸

Fort Myers, Florida, United States

National Ophthalmic Research Institute at Retina Consultants of SW Florida (site 270)

🇺🇸

Fort Myers, Florida, United States

Retina Consultants San Diego (site 232)

🇺🇸

Poway, California, United States

The Eye Care Group, PC (site 315)

🇺🇸

Waterbury, Connecticut, United States

Retinal Consultants Medical Group (site 289)

🇺🇸

Sacramento, California, United States

Orange County Retina Medical Group (site 252)

🇺🇸

Santa Ana, California, United States

Florida Eye Clinic (site 257)

🇺🇸

Altamonte Springs, Florida, United States

Northern California Retina Vitreous Associates (site 320)

🇺🇸

Mountain View, California, United States

Sunnybrook Health Sciences Centre (site 305)

🇨🇦

Toronto, Ontario, Canada

Retina Specialists (site 231)

🇺🇸

Towson, Maryland, United States

Retina Research Institute of Texas, L.L.C. (site 269)

🇺🇸

Abilene, Texas, United States

Southeast Retina Center (site 268)

🇺🇸

Augusta, Georgia, United States

Capital Region Retina (site 316)

🇺🇸

Albany, New York, United States

Eye Foundation of Kansas City Truman Medical Center (site 272)

🇺🇸

Kansas City, Missouri, United States

Retina Associates St. Louis (site 300)

🇺🇸

Florissant, Missouri, United States

Retina-Vitreous Consultants (site 216)

🇺🇸

Livingston, New Jersey, United States

Austin Retina Associates (site 304)

🇺🇸

Austin, Texas, United States

Carolina Eye Associates (site 308)

🇺🇸

Southern Pines, North Carolina, United States

Eyesight Ophthalmic Services, PA (site 290)

🇺🇸

Portsmouth, New Hampshire, United States

Delaware Valley Retina Associates (site 261)

🇺🇸

Lawrenceville, New Jersey, United States

Retina Associates of Cleveland, Inc. (site 219)

🇺🇸

Lakewood, Ohio, United States

Retina-Vitreous Associates (site 266)

🇺🇸

Toledo, Ohio, United States

New York Eye & Ear Infirmary (site 272)

🇺🇸

New York, New York, United States

Vitreo-Retinal Consultants & Surgeons, P.A. (site 274)

🇺🇸

Wichita, Kansas, United States

Retina Associates, PA (site 295)

🇺🇸

Shawnee Mission, Kansas, United States

Associated Retina Consultants (site 286)

🇺🇸

Phoenix, Arizona, United States

Retinal Consultants of Arizona (site 209)

🇺🇸

Phoenix, Arizona, United States

Midwest Eye Institute (site 253)

🇺🇸

Indianapolis, Indiana, United States

Retinal Consultants of Nevada (site 273)

🇺🇸

Las Vegas, Nevada, United States

Cincinnati Eye Institute (site 285)

🇺🇸

Cincinnati, Ohio, United States

Houston Eye Associates (site 321)

🇺🇸

Houston, Texas, United States

Rocky Mountain Retina Consultants (site 256)

🇺🇸

Salt Lake City, Utah, United States

University of Utah, John A. Moran Eye Center (site 205)

🇺🇸

Salt Lake City, Utah, United States

Eye Centre Pasqua Hospital (site 299)

🇨🇦

Regina, Saskatchewan, Canada

Retina Centers PC (site 215)

🇺🇸

Tucson, Arizona, United States

Magruder Eye Institute (site 264)

🇺🇸

Orlando, Florida, United States

Southern Vitreoretinal Associates, PL (site 309)

🇺🇸

Tallahassee, Florida, United States

Center for Retina and Macular Disease (site 293)

🇺🇸

Winter Haven, Florida, United States

Vitreous-Retina-Macula Consultants of New York (site 239)

🇺🇸

New York, New York, United States

Black Hills Regional Eye Institute (site 202)

🇺🇸

Rapid City, South Dakota, United States

Ophthalmology Associates of PA (site 297)

🇺🇸

Bala Cynwyd, Pennsylvania, United States

Retina Research Center (site 204)

🇺🇸

Austin, Texas, United States

Ivey Eye Institute (site 314)

🇨🇦

London, Ontario, Canada

Palmetto Retina Center (site 275)

🇺🇸

West Columbia, South Carolina, United States

Eye Centers of Louisville (site 251)

🇺🇸

Louisville, Kentucky, United States

Calgary Retina Consultants (site 318)

🇨🇦

Calgary, Alberta, Canada

Eye Care Associates of East Texas (site 282)

🇺🇸

Tyler, Texas, United States

Southeastern Retina Associates, PC (Site 250)

🇺🇸

Knoxville, Tennessee, United States

Retina Associates of Cleveland (site 228)

🇺🇸

Beachwood, Ohio, United States

University of Texas Medical Branch- Galveston (site 301

🇺🇸

Galveston, Texas, United States

University of Virginia- Ophthalmology Dept. (site 254)

🇺🇸

Charlottesville, Virginia, United States

Valley Retina Institue, PA (site 258)

🇺🇸

McAllen, Texas, United States

Canadian Centre for Advanced Eye Therapeutics (site 291)

🇨🇦

Mississauga, Ontario, Canada

University of South Florida Eye Institute (site 311)

🇺🇸

Tampa, Florida, United States

Retina and Vitreous Center of Southern Oregon (site 271)

🇺🇸

Ashland, Oregon, United States

Retina Associates of New Jersey (site 298)

🇺🇸

Teaneck, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath